A double board-certified foot and ankle surgeon with expertise in trauma, sports injuries, and complex reconstructive procedures, Dr. Ali will expand access to comprehensive podiatric care in the growing Acworth community.
Read More
While Patients Suffer, DEA Manipulates Due Process to Cover Its Cannabis Crimes. The DEA blocking federally compliant pharmaceutical research is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice.
Read More
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin
Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action
Mentavi's innovative online asynchronous assessment, validated in a clinical study presented at the 10th World Congress on ADHD, provides clinicians with an efficient, comprehensive diagnostic mental health evaluation at an affordable price for their patients.
Read More
While busting cartels, DEA continues war on science and suffering patients. Duane Boise, CEO of MMJ International Holdings, expressed frustration over the contrasting approaches of federal agencies, stating, "While the FDA is facilitating medical innovation, the DEA's hindrance not only blocks scientific progress but also contradicts directives aimed at revitalizing domestic manufacturing." This situation starkly contrasts with the "Buy American" initiative endorsed by President Trump, which was intended to strengthen U.S. drug production capabilities and reduce dependence on foreign manufacturers.
Jeff Clark's Final Vision 2025 reveals expert-vetted tech stock picks in AI, biotech, and quantum computing-built on proven options strategies, chaos pattern analysis, and actionable investment timelines for serious traders seeking growth in a volatile market.
Read More
A Groundbreaking 28-Day Brain Health Plan from Dr. Will Mitchell Uses Coconut Oil, B Vitamins, and Science-Backed Nutrition to Help Adults Over 45 Combat Memory Decline, Restore Mental Clarity, and Build Long-Term Cognitive Resilience in 2025
Read MoreSKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs
Read More
The Chronic Kidney Disease Solution introduces a science-backed 3-phase system for natural kidney support in 2025 - focusing on the gut-kidney axis, inflammation reduction, and lifestyle-based recovery across all CKD stages.
Read More
Dual siRNA Therapeutic Confirms Its Robust In Vivo Results, Strongly De-Risking the Clinical Path and Underscoring CCT-217's Potential as a Transformative, Patient-Friendly Therapy for Obesity and Metabolic Disorders
Read MoreCompany strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globally
Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Jaguar CEO Lisa Conte presenting July 17 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Read MoreSpikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Read More
UltraClear laser is now available at The Naderi Center, offering safe, effective skin resurfacing for all skin tones with reduced downtime and heat-related risks.
Read MoreAinos Pioneers SmellTech as the Next Sensory Frontier in Industrial AI
2H 2025 Industrial Pilots and Subscription Model Poised to Unlock Multi-Million Dollar Revenue Potential in 2026
Read More
The DEA Diversion Control Problem: A Hidden Threat to U.S. Pharmaceutical Manufacturing ?
Take the case of MMJ BioPharma Cultivation - despite submissions of FDA Investigational New Drug (IND) applications and Orphan Drug Designation approval for treating Huntington's Disease - has been blocked from manufacturing cannabis-derived pharmaceuticals by the DEA, under the leadership of Deputy Administrator Thomas Prevoznik.
Read More
New 2025 Review Highlights How Dentitox Pro's Liquid Formula Combines Vitamins, Minerals, and Plant-Based Extracts to Support Gum Health, Strengthen Teeth, and Address Root Causes of Oral Inflammation Naturally
Read MoreFirst comprehensive sell-side report on TRNR cites more than 800% growth in expected 2025 revenue
Valuation driven by stock-for-stock M&A model and potential crypto-treasury upside
Read More
Early positive consumer testimonials from initial Company product sampling
Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout market
Developed through over a decade of scientific research to deliver a patent-pending, fast-acting supplement formulation for maximum effect
Completed initial production in four flavors
Aspire to launch BUZZ BOMB™ at the FITCON and Fit Expo conventions in August
HITRUST certification validates that AGFA HealthCare is operating using leading security practices to protect sensitive information.
Read More
A science-backed review of Visium Pro's herbal formula reveals how this top-rated eye supplement helps reduce digital eye strain, improve night vision, and support long-term ocular health in 2025.
Read More
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications
Read More
CBD Life Sciences Inc. (OTC:CBDL) expands its digital advertising arsenal through the Vibe Performance Network, positioning its flagship 8000MG Pain Cream in front of millions of engaged, wellness-focused viewers - unlocking massive revenue potential and long-term shareholder value in the booming CBD market.
Read More
- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -
- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -
Read More
From Plant to Pill: MMJ-001 Marks a Pharmaceutical First in Cannabis Medicine with FDA-Grade Formulation for a Devastating Neurological Disorder while awaiting final FDA approval for use in clinical trials.
Read More